Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Wed Apr 02 10:46:13 GMT 2025
by
admin
on
Wed Apr 02 10:46:13 GMT 2025
|
| Protein Type | BISPECIFIC ANTIBODY |
| Protein Sub Type | IGG4 |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
Z8TW7Z7LJD
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C213417
Created by
admin on Wed Apr 02 10:46:13 GMT 2025 , Edited by admin on Wed Apr 02 10:46:13 GMT 2025
|
PRIMARY | |||
|
300000015484
Created by
admin on Wed Apr 02 10:46:13 GMT 2025 , Edited by admin on Wed Apr 02 10:46:13 GMT 2025
|
PRIMARY | |||
|
13188
Created by
admin on Wed Apr 02 10:46:13 GMT 2025 , Edited by admin on Wed Apr 02 10:46:13 GMT 2025
|
PRIMARY | |||
|
2918752-58-4
Created by
admin on Wed Apr 02 10:46:13 GMT 2025 , Edited by admin on Wed Apr 02 10:46:13 GMT 2025
|
PRIMARY | |||
|
Z8TW7Z7LJD
Created by
admin on Wed Apr 02 10:46:13 GMT 2025 , Edited by admin on Wed Apr 02 10:46:13 GMT 2025
|
PRIMARY |
| From | To |
|---|---|
| 4_134 | 4_194 |
| 4_23 | 4_88 |
| 3_134 | 3_194 |
| 3_23 | 3_88 |
| 2_537 | 2_636 |
| 2_367 | 2_425 |
| 2_261 | 2_321 |
| 2_147 | 2_203 |
| 2_134 | 4_214 |
| 2_22 | 2_95 |
| 1_537 | 1_636 |
| 1_367 | 1_425 |
| 1_261 | 1_321 |
| 1_229 | 2_229 |
| 1_226 | 2_226 |
| 1_147 | 1_203 |
| 1_134 | 3_214 |
| 1_22 | 1_95 |
| Glycosylation Type | MAMMALIAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_297 |
| N | 2_297 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
Clustering of 4-1BB on the surface of T cells leads to T cell activation
PRECLINICAL
|
||
|
TARGET -> INHIBITOR |
PRECLINICAL
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
Clustering of 4-1BB on the surface of T cells leads to T cell activation, proliferation, and cytokine secretion. The mode of action of PRS-344 is to promote 4-1BB clustering by bridging 4-1BB-positive T cells with PD-L1-positive tumor cells, providing a potent co-stimulatory signal to tumor antigen-specific T cells. PRS-344 is intended to localize 4-1BB activation in the tumor in a PD-L1-dependent manner
|
Structural Modifications
| Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
|---|---|---|---|---|---|---|
| AMINO_ACID_SUBSTITUTION | [1_1] [2_1] | N-TERMINUS | Q | PIDOLIC ACID | SZB83O1W42 |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|
||||
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|